Elie Naddaf, Thi Kim Oanh Nguyen, Jens O. Watzlawik, Huanyao Gao, Xu Hou, Fabienne C. Fiesel, Jay Mandrekar, Eileen Kokesh, William S. Harmsen, Ian R. Lanza, Wolfdieter Springer, Eugenia Trushina
BackgroundInclusion body myositis (IBM) is the most prevalent muscle disease in adults for which no current treatment exists. The pathogenesis of IBM remains poorly defined. In this study, we aimed to explore the interplay between inflammation and mitochondrial dysfunction in IBM.MethodsThe study population consisted of 38 IBM patients and 22 age‐ and sex‐matched controls without a myopathy. Mean age was 62.9 years (SD = 9) in IBM group and 59.7 (10) in controls. Bulk RNA sequencing, Meso Scale Discovery electrochemiluminescence (ECL), western blotting, histochemistry and immunohistochemistry were performed on frozen muscle samples from the study participants.ResultsWe demonstrated activation of the NLRP3 inflammasome in IBM muscle samples, with the NLRP3 inflammasome being the most upregulated pathway on RNA sequencing, along with increased expression of NLRP3 and ASC proteins in IBM group. <jats:italic>NLRP3</jats:italic> RNA levels most strongly correlated with <jats:italic>TLR7</jats:italic> (correlation coefficient <jats:italic>ρ</jats:italic> = 0.91) and complement activation‐related genes, and inversely correlated with several mitochondria‐related genes among others. On muscle histopathology, there was increased NRLP3 immunoreactivity in both inflammatory cells and muscle fibres. Mitophagy is critical for removing damaged mitochondria and preventing the formation of a vicious cycle of mitochondrial dysfunction—NLRP3 inflammasome activation. Herein, we showed altered mitophagy, as witnessed by the elevated levels of p‐S65‐Ubiquitin, a mitophagy marker, in muscle lysates from IBM patients compared to controls (median of 114.3 vs. 81.25 ECL units, <jats:italic>p</jats:italic> = 0.005). The p‐S65‐Ubiquitin levels were most significantly elevated in IBM males compared to male controls (136 vs. 83.5 ECL units; <jats:italic>p</jats:italic> = 0.013), whereas IBM females had milder nonsignificant elevation compared to female controls (97.25 vs. 69 ECL units, <jats:italic>p</jats:italic> = 0.31). On muscle histopathology, p‐S65‐Ubiquitin aggregates accumulated in muscle fibres that were mostly Type 2 and devoid of cytochrome‐c‐oxidase reactivity. <jats:italic>NLRP3 RNA</jats:italic> levels correlated with p‐S65‐Ubiquitin levels in both sexes (males: <jats:italic>ρ</jats:italic> = 0.48, females: <jats:italic>ρ</jats:italic> = 0.54) but with loss of muscle strength, as reflected by the manual motor test score, only in males (males: <jats:italic>ρ</jats:italic> = 0.62, females: <jats:italic>ρ</jats:italic> = −0.14). Lastly, we identified sex‐specific molecular pathways in IBM. Females had upregulation of pathways related to response to stress, which could conceivably offset some of the pathomechanisms of IBM, while males had upregulation of pathways related to cell adhesion and migration.ConclusionsThere is activation of the NLRP3 inflammasome in IBM, along with altered mitophagy, particularly in males, which is of potential therapeutic significance. T
{"title":"NLRP3 Inflammasome Activation and Altered Mitophagy Are Key Pathways in Inclusion Body Myositis","authors":"Elie Naddaf, Thi Kim Oanh Nguyen, Jens O. Watzlawik, Huanyao Gao, Xu Hou, Fabienne C. Fiesel, Jay Mandrekar, Eileen Kokesh, William S. Harmsen, Ian R. Lanza, Wolfdieter Springer, Eugenia Trushina","doi":"10.1002/jcsm.13672","DOIUrl":"https://doi.org/10.1002/jcsm.13672","url":null,"abstract":"BackgroundInclusion body myositis (IBM) is the most prevalent muscle disease in adults for which no current treatment exists. The pathogenesis of IBM remains poorly defined. In this study, we aimed to explore the interplay between inflammation and mitochondrial dysfunction in IBM.MethodsThe study population consisted of 38 IBM patients and 22 age‐ and sex‐matched controls without a myopathy. Mean age was 62.9 years (SD = 9) in IBM group and 59.7 (10) in controls. Bulk RNA sequencing, Meso Scale Discovery electrochemiluminescence (ECL), western blotting, histochemistry and immunohistochemistry were performed on frozen muscle samples from the study participants.ResultsWe demonstrated activation of the NLRP3 inflammasome in IBM muscle samples, with the NLRP3 inflammasome being the most upregulated pathway on RNA sequencing, along with increased expression of NLRP3 and ASC proteins in IBM group. <jats:italic>NLRP3</jats:italic> RNA levels most strongly correlated with <jats:italic>TLR7</jats:italic> (correlation coefficient <jats:italic>ρ</jats:italic> = 0.91) and complement activation‐related genes, and inversely correlated with several mitochondria‐related genes among others. On muscle histopathology, there was increased NRLP3 immunoreactivity in both inflammatory cells and muscle fibres. Mitophagy is critical for removing damaged mitochondria and preventing the formation of a vicious cycle of mitochondrial dysfunction—NLRP3 inflammasome activation. Herein, we showed altered mitophagy, as witnessed by the elevated levels of p‐S65‐Ubiquitin, a mitophagy marker, in muscle lysates from IBM patients compared to controls (median of 114.3 vs. 81.25 ECL units, <jats:italic>p</jats:italic> = 0.005). The p‐S65‐Ubiquitin levels were most significantly elevated in IBM males compared to male controls (136 vs. 83.5 ECL units; <jats:italic>p</jats:italic> = 0.013), whereas IBM females had milder nonsignificant elevation compared to female controls (97.25 vs. 69 ECL units, <jats:italic>p</jats:italic> = 0.31). On muscle histopathology, p‐S65‐Ubiquitin aggregates accumulated in muscle fibres that were mostly Type 2 and devoid of cytochrome‐c‐oxidase reactivity. <jats:italic>NLRP3 RNA</jats:italic> levels correlated with p‐S65‐Ubiquitin levels in both sexes (males: <jats:italic>ρ</jats:italic> = 0.48, females: <jats:italic>ρ</jats:italic> = 0.54) but with loss of muscle strength, as reflected by the manual motor test score, only in males (males: <jats:italic>ρ</jats:italic> = 0.62, females: <jats:italic>ρ</jats:italic> = −0.14). Lastly, we identified sex‐specific molecular pathways in IBM. Females had upregulation of pathways related to response to stress, which could conceivably offset some of the pathomechanisms of IBM, while males had upregulation of pathways related to cell adhesion and migration.ConclusionsThere is activation of the NLRP3 inflammasome in IBM, along with altered mitophagy, particularly in males, which is of potential therapeutic significance. T","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"20 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wenjie Wang, Feijie Wang, Yihan Li, Yuwei Shi, Xiaoyan Wang, Xinyu Chen, Weifang Zheng, Julianna C. Hsing, Ying Lu, Yi‐Shuan Wu, Ann W. Hsing, Juntao Kan, Wei He, Shankuan Zhu
BackgroundNormal weight obesity (NWO) is characterized by excess body fat in individuals with normal body mass index (BMI). This study aimed to investigate gut microbiota alterations in NWO and their potential associations with cardiometabolic diseases (CMD) risk in two independent cohorts.MethodsOur NWO‐CMD mortality analysis included 168 099 adults with normal BMI from two large open‐access databases, while our NWO‐gut microbiota study involved 5467 adults with normal BMI from two independent cohorts: the WELL‐China cohort and the Lanxi cohort. NWO was defined as having a normal BMI (18.5–23.9 kg/m<jats:sup>2</jats:sup>) but an excess per cent body fat (PBF, ≥ 25% in men and ≥ 35% in women). Normal weight lean was defined as having a normal BMI and normal PBF. The 16S rRNA gene sequencing method was used to analyse gut microbiota data.ResultsThe study comprised 3620 (64.0% female, median age 58 years) and 1847 (64.3% female, median age 56 years) participants from the WELL‐China and Lanxi cohorts. In our meta‐analysis, NWO is associated with 26% (95% CI: 1.07–1.41) higher risk of CMD mortality. Gut microbial analyses indicated that the NWO group exhibited reduced levels of observed species (<jats:italic>p</jats:italic> = 0.009 and <jats:italic>p</jats:italic> = 0.013) and Chao 1 index (<jats:italic>p</jats:italic> = 0.002 and <jats:italic>p</jats:italic> = 0.002) and altered gut microbial compositions (<jats:italic>p</jats:italic> = 0.009 and <jats:italic>p</jats:italic> < 0.001) compared with the NWL group. Seven genera were consistently observed to be associated with NWO in both two cohorts (all Q < 0.25). Among them, five (<jats:italic>Fusobacterium</jats:italic>, <jats:italic><jats:styled-content style="fixed-case">Ruminococcus gnavus</jats:styled-content> group</jats:italic>, <jats:italic><jats:styled-content style="fixed-case">Ruminococcus torques</jats:styled-content> group</jats:italic>, <jats:italic>Coprococcus</jats:italic> and <jats:italic>Christensenellaceae_R7_group</jats:italic>) have been previously linked to obesity, while the other two (<jats:italic>Phascolarctobacterium</jats:italic> and <jats:italic>Clostridia_UCG‐014</jats:italic>) were minimally reported. We also found statistically significant differences in the microbial composition between the NWO group and the obesity group (<jats:italic>p</jats:italic> = 0.001 and <jats:italic>p</jats:italic> = 0.001). Furthermore, the NWO‐related gut microbiome was associated with an elevated risk of hypertension, dyslipidaemia and metabolic syndrome, the corresponding HR (95% CIs) were 1.11 (1.01–1.22), 1.19 (1.10–1.29) and 1.17 (1.05–1.30) in the WELL‐China cohort and 1.14 (1.02–1.27), 1.15 (1.02–1.29) and 1.16 (1.02–1.32) in the Lanxi cohort.ConclusionsThese two large cohorts provided reliable evidence that gut microbiota alterations in NWO resemble those found in obesity, yet also display unique aspects. This distinct microbiota profile may contribute to heightened cardiometa
{"title":"Distinct Gut Microbiota Profiles in Normal Weight Obesity and Their Association With Cardiometabolic Diseases: Results From Two Independent Cohort Studies","authors":"Wenjie Wang, Feijie Wang, Yihan Li, Yuwei Shi, Xiaoyan Wang, Xinyu Chen, Weifang Zheng, Julianna C. Hsing, Ying Lu, Yi‐Shuan Wu, Ann W. Hsing, Juntao Kan, Wei He, Shankuan Zhu","doi":"10.1002/jcsm.13644","DOIUrl":"https://doi.org/10.1002/jcsm.13644","url":null,"abstract":"BackgroundNormal weight obesity (NWO) is characterized by excess body fat in individuals with normal body mass index (BMI). This study aimed to investigate gut microbiota alterations in NWO and their potential associations with cardiometabolic diseases (CMD) risk in two independent cohorts.MethodsOur NWO‐CMD mortality analysis included 168 099 adults with normal BMI from two large open‐access databases, while our NWO‐gut microbiota study involved 5467 adults with normal BMI from two independent cohorts: the WELL‐China cohort and the Lanxi cohort. NWO was defined as having a normal BMI (18.5–23.9 kg/m<jats:sup>2</jats:sup>) but an excess per cent body fat (PBF, ≥ 25% in men and ≥ 35% in women). Normal weight lean was defined as having a normal BMI and normal PBF. The 16S rRNA gene sequencing method was used to analyse gut microbiota data.ResultsThe study comprised 3620 (64.0% female, median age 58 years) and 1847 (64.3% female, median age 56 years) participants from the WELL‐China and Lanxi cohorts. In our meta‐analysis, NWO is associated with 26% (95% CI: 1.07–1.41) higher risk of CMD mortality. Gut microbial analyses indicated that the NWO group exhibited reduced levels of observed species (<jats:italic>p</jats:italic> = 0.009 and <jats:italic>p</jats:italic> = 0.013) and Chao 1 index (<jats:italic>p</jats:italic> = 0.002 and <jats:italic>p</jats:italic> = 0.002) and altered gut microbial compositions (<jats:italic>p</jats:italic> = 0.009 and <jats:italic>p</jats:italic> < 0.001) compared with the NWL group. Seven genera were consistently observed to be associated with NWO in both two cohorts (all Q < 0.25). Among them, five (<jats:italic>Fusobacterium</jats:italic>, <jats:italic><jats:styled-content style=\"fixed-case\">Ruminococcus gnavus</jats:styled-content> group</jats:italic>, <jats:italic><jats:styled-content style=\"fixed-case\">Ruminococcus torques</jats:styled-content> group</jats:italic>, <jats:italic>Coprococcus</jats:italic> and <jats:italic>Christensenellaceae_R7_group</jats:italic>) have been previously linked to obesity, while the other two (<jats:italic>Phascolarctobacterium</jats:italic> and <jats:italic>Clostridia_UCG‐014</jats:italic>) were minimally reported. We also found statistically significant differences in the microbial composition between the NWO group and the obesity group (<jats:italic>p</jats:italic> = 0.001 and <jats:italic>p</jats:italic> = 0.001). Furthermore, the NWO‐related gut microbiome was associated with an elevated risk of hypertension, dyslipidaemia and metabolic syndrome, the corresponding HR (95% CIs) were 1.11 (1.01–1.22), 1.19 (1.10–1.29) and 1.17 (1.05–1.30) in the WELL‐China cohort and 1.14 (1.02–1.27), 1.15 (1.02–1.29) and 1.16 (1.02–1.32) in the Lanxi cohort.ConclusionsThese two large cohorts provided reliable evidence that gut microbiota alterations in NWO resemble those found in obesity, yet also display unique aspects. This distinct microbiota profile may contribute to heightened cardiometa","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"299 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leo R. Brown, Maria Soupashi, Michael S. Yule, Danielle R. Clyde, Ellen Gardner, Charlotte Smith, Ahmed Dhaif, Barry J. A. Laird, Stephen J. Wigmore, Richard J. E. Skipworth
BackgroundSingle‐slice computed tomography (CT) body composition has been studied extensively for prognostication in patients with cancer. New software packages can also provide multi‐slice volumetric measurements, but the clinical utility of these remains under explored. This study aimed to evaluate the agreement between single‐ and multi‐slice body composition analyses in patients with oesophagogastric cancer and to explore the association between these measures and overall survival.MethodsConsecutive patients with newly diagnosed oesophagogastric (OG) cancer were identified through the prospectively maintained regional database of the South East Scotland Cancer Network across a 2‐year study period. CT body composition analyses were undertaken using scans collected during routine clinical care. Single‐slice (cross‐sectional area at mid L3) and multi‐slice (volume between T12 and L4) measurements were compared for skeletal muscle (SKM), subcutaneous adipose (SAT), visceral adipose (VAT) and intermuscular adipose (IMAT). Agreement between sex‐stratified z‐scores was quantified using Pearson correlation coefficients and Bland–Altman analyses. Cox proportional hazard modelling was used to estimate the effect of these measures on overall survival.ResultsOverall, 504 patients (67.9% male, median 72 years) were newly diagnosed with OG cancer during the study period. Single‐ and multi‐slice (mean: 169 slices) measurements correlated highly for SKM (R: 0.97, p < 0.001), SAT (R: 0.98, p < 0.001), VAT (R: 0.97, p < 0.001), SKM radiodensity (R: 0.93, p < 0.001) and IMAT (R: 0.88, p < 0.001). Bias on Bland–Altman analysis was 0.00 for all tissue measurements. Limits of agreement (LoA) were narrowest for SAT (±0.43), VAT (±0.46) and SKM (±0.48), but slightly wider for SKM radiodensity (±0.73) and IMAT (±0.96). Adipose tissue ‘outliers’ (those where agreement between single‐ and multi‐slice z‐scores was outside the LoA) had a higher median weight and body mass index (BMI), suggestive of poorer agreement in patients with obesity. Sensitivity analysis, excluding those with BMI > 30, narrowed the LoA for SKM, VAT, SAT and IMAT. Direction and magnitudes of observed effect sizes for overall survival were all highly comparable, with hazard ratios for each tissue type varying by ≤ 0.04 between single‐ and multi‐slice adjusted estimates.ConclusionsSingle‐slice and multi‐slice CT assessments provide highly correlated tissue measurements amongst patients with OG cancer. Associations between these measurements and overall survival were also comparable across both types of body composition analysis. Agreement between single‐ and multi‐slice measurements of adiposity is worse in patients with obesity, suggesting single‐slice analyses may less accurately reflect the quantity or distribution of adipose tissue in this patient group.
{"title":"Comparison Between Single‐ and Multi‐slice Computed Tomography Body Composition Analysis in Patients With Oesophagogastric Cancer","authors":"Leo R. Brown, Maria Soupashi, Michael S. Yule, Danielle R. Clyde, Ellen Gardner, Charlotte Smith, Ahmed Dhaif, Barry J. A. Laird, Stephen J. Wigmore, Richard J. E. Skipworth","doi":"10.1002/jcsm.13673","DOIUrl":"https://doi.org/10.1002/jcsm.13673","url":null,"abstract":"BackgroundSingle‐slice computed tomography (CT) body composition has been studied extensively for prognostication in patients with cancer. New software packages can also provide multi‐slice volumetric measurements, but the clinical utility of these remains under explored. This study aimed to evaluate the agreement between single‐ and multi‐slice body composition analyses in patients with oesophagogastric cancer and to explore the association between these measures and overall survival.MethodsConsecutive patients with newly diagnosed oesophagogastric (OG) cancer were identified through the prospectively maintained regional database of the South East Scotland Cancer Network across a 2‐year study period. CT body composition analyses were undertaken using scans collected during routine clinical care. Single‐slice (cross‐sectional area at mid L3) and multi‐slice (volume between T12 and L4) measurements were compared for skeletal muscle (SKM), subcutaneous adipose (SAT), visceral adipose (VAT) and intermuscular adipose (IMAT). Agreement between sex‐stratified z‐scores was quantified using Pearson correlation coefficients and Bland–Altman analyses. Cox proportional hazard modelling was used to estimate the effect of these measures on overall survival.ResultsOverall, 504 patients (67.9% male, median 72 years) were newly diagnosed with OG cancer during the study period. Single‐ and multi‐slice (mean: 169 slices) measurements correlated highly for SKM (R: 0.97, <jats:italic>p</jats:italic> < 0.001), SAT (R: 0.98, <jats:italic>p</jats:italic> < 0.001), VAT (R: 0.97, <jats:italic>p</jats:italic> < 0.001), SKM radiodensity (R: 0.93, <jats:italic>p</jats:italic> < 0.001) and IMAT (R: 0.88, p < 0.001). Bias on Bland–Altman analysis was 0.00 for all tissue measurements. Limits of agreement (LoA) were narrowest for SAT (±0.43), VAT (±0.46) and SKM (±0.48), but slightly wider for SKM radiodensity (±0.73) and IMAT (±0.96). Adipose tissue ‘outliers’ (those where agreement between single‐ and multi‐slice z‐scores was outside the LoA) had a higher median weight and body mass index (BMI), suggestive of poorer agreement in patients with obesity. Sensitivity analysis, excluding those with BMI > 30, narrowed the LoA for SKM, VAT, SAT and IMAT. Direction and magnitudes of observed effect sizes for overall survival were all highly comparable, with hazard ratios for each tissue type varying by ≤ 0.04 between single‐ and multi‐slice adjusted estimates.ConclusionsSingle‐slice and multi‐slice CT assessments provide highly correlated tissue measurements amongst patients with OG cancer. Associations between these measurements and overall survival were also comparable across both types of body composition analysis. Agreement between single‐ and multi‐slice measurements of adiposity is worse in patients with obesity, suggesting single‐slice analyses may less accurately reflect the quantity or distribution of adipose tissue in this patient group.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"32 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brandon Stretton, Joshua Kovoor, Aashray Gupta, Stephen Bacchi
{"title":"Anorexia of Ageing, an Underappreciated Perioperative Concern?","authors":"Brandon Stretton, Joshua Kovoor, Aashray Gupta, Stephen Bacchi","doi":"10.1002/jcsm.13683","DOIUrl":"https://doi.org/10.1002/jcsm.13683","url":null,"abstract":"","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"22 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rachana Mehta, Ashok Kumar Balaraman, Muhammed Shabil, Sanjit Sah
<p>We read with great interest the article titled ‘Association of computed tomography-derived body composition and complications after colorectal cancer surgery A systematic review and meta-analysis’ and commend the authors for their rigorous and insightful systematic review and meta-analysis on body composition measurements using computed tomography (CT) scans as predictors of complications following colorectal cancer surgery [<span>1</span>]. This research addresses a highly relevant clinical issue, providing valuable information to guide surgical decision-making. While the article provides important findings, we believe there are some additional aspects that could further strengthen its impact and provide readers with an even more comprehensive understanding.</p> <p>First, although the authors conducted a thorough risk of bias assessment using the QUIPS tool, the article does not mention whether a sensitivity analysis was performed based on study quality. We suggest conducting such an analysis to examine how excluding lower-quality studies (e.g., those rated as having a high risk of bias) may impact the pooled results. Sensitivity analysis could help readers better appreciate the robustness of the findings and determine whether the conclusions are consistent across studies with varying levels of methodological rigour [<span>2</span>].</p> <p>Second, the certainty of evidence presented in this study could have been evaluated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) framework. GRADE is widely recognized for systematically assessing the quality of evidence and the strength of recommendations in health care research. Including a GRADE assessment would allow the readers to understand the confidence in the results across different outcomes, especially given the variability in CT measurement methods and clinical endpoints considered in the studies [<span>3</span>]. This would also facilitate the translation of evidence into clinical practice by offering clarity on the reliability of the conclusions.</p> <p>Third, while the authors rightfully address the risk of publication bias in the discussion, we recommend the inclusion of formal statistical methods to assess this risk. A funnel plot or DOI plot, alongside statistical tests such as Egger's regression or the trim-and-fill method, could provide more concrete evidence of the presence or absence of publication bias [<span>4</span>]. These methods would further substantiate the robustness of the meta-analytic findings by ensuring that the results were not disproportionately influenced by small or positive-result studies.</p> <p>Furthermore, it might be valuable to explore subgroup analyses based on factors such as the specific CT measurement (e.g., visceral fat vs. sarcopenia), patient age, or cancer stage. These analyses could uncover potential variations in predictive utility across different patient populations, making the results more clinically actionab
{"title":"Comment on ‘Association of Computed Tomography‐Derived Body Composition and Complications After Colorectal Cancer Surgery: A Systematic Review and Meta‐Analysis’ by Van Helsdingen et al.","authors":"Rachana Mehta, Ashok Kumar Balaraman, Muhammed Shabil, Sanjit Sah","doi":"10.1002/jcsm.13679","DOIUrl":"https://doi.org/10.1002/jcsm.13679","url":null,"abstract":"<p>We read with great interest the article titled ‘Association of computed tomography-derived body composition and complications after colorectal cancer surgery A systematic review and meta-analysis’ and commend the authors for their rigorous and insightful systematic review and meta-analysis on body composition measurements using computed tomography (CT) scans as predictors of complications following colorectal cancer surgery [<span>1</span>]. This research addresses a highly relevant clinical issue, providing valuable information to guide surgical decision-making. While the article provides important findings, we believe there are some additional aspects that could further strengthen its impact and provide readers with an even more comprehensive understanding.</p>\u0000<p>First, although the authors conducted a thorough risk of bias assessment using the QUIPS tool, the article does not mention whether a sensitivity analysis was performed based on study quality. We suggest conducting such an analysis to examine how excluding lower-quality studies (e.g., those rated as having a high risk of bias) may impact the pooled results. Sensitivity analysis could help readers better appreciate the robustness of the findings and determine whether the conclusions are consistent across studies with varying levels of methodological rigour [<span>2</span>].</p>\u0000<p>Second, the certainty of evidence presented in this study could have been evaluated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) framework. GRADE is widely recognized for systematically assessing the quality of evidence and the strength of recommendations in health care research. Including a GRADE assessment would allow the readers to understand the confidence in the results across different outcomes, especially given the variability in CT measurement methods and clinical endpoints considered in the studies [<span>3</span>]. This would also facilitate the translation of evidence into clinical practice by offering clarity on the reliability of the conclusions.</p>\u0000<p>Third, while the authors rightfully address the risk of publication bias in the discussion, we recommend the inclusion of formal statistical methods to assess this risk. A funnel plot or DOI plot, alongside statistical tests such as Egger's regression or the trim-and-fill method, could provide more concrete evidence of the presence or absence of publication bias [<span>4</span>]. These methods would further substantiate the robustness of the meta-analytic findings by ensuring that the results were not disproportionately influenced by small or positive-result studies.</p>\u0000<p>Furthermore, it might be valuable to explore subgroup analyses based on factors such as the specific CT measurement (e.g., visceral fat vs. sarcopenia), patient age, or cancer stage. These analyses could uncover potential variations in predictive utility across different patient populations, making the results more clinically actionab","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"41 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Smith Giri, Christian Harmon, Daniel Hess, Elizabeth M. Cespedes Feliciano, Ijeamaka Anyene Fumagalli, Bette Caan, Leon Lenchik, Karteek Popuri, Vincent Chow, Mirza Faisal Beg, Smita Bhatia, Grant R. Williams
BackgroundOlder adults with cancer are at an increased risk of treatment related toxicities and early death. Routinely collected clinico‐demographic characteristics inadequately explain this increased risk limiting accurate prognostication. Prior studies have suggested that altered body composition and frailty are independently associated with worse survival among older adults with cancer; however, their combined influence remains unclear.MethodsWe used data from a single‐institution prospective cohort study of older adults (≥ 60 years) who underwent geriatric assessment (GA) at the time of initial consultation with a medical oncologist from September 2017 to December 2020 and available baseline abdominal computed tomography within 60 days of GA. Using multi‐slice CT images from T12 to L5 level, we assessed volumetric measures of skeletal muscle (SMV), visceral adipose tissue (VATV), subcutaneous adipose tissue (SATV) and averaged skeletal muscle density (SMD), computing sex‐specific z for each measure. Frailty was measured using a 44‐item frailty index using the deficit accumulation approach. Primary outcome of interest was overall survival (OS) defined as time from GA to death or last follow up. We used multivariable Cox regression model to study the independent association between the above four body composition measurements and OS adjusted for baseline confounders and frailty.ResultsWe included 459 patients with a mean age of 69.7 ± 7.5 years, 60% males and 77% non‐Hispanic Whites. Most had colorectal (27%) or pancreatic cancer (20%) and 48% had stage IV disease. Over a median follow up of 39.4 months, 209 patients (46%) died. In multivariable Cox regression models adjusted for age, sex, race, cancer type, cancer stage and frailty, skeletal muscle volume (HR 0.74; 95% CI 0.58–0.96; p = 0.02, per 1 SD increment) was independently associated with OS. The addition of body composition variables to baseline clinico‐demographic variables and frailty led to a slightly improved model discrimination.ConclusionsSMV is independently associated with OS among older adults with newly diagnosed gastrointestinal cancers. Capturing body composition measurements in oncology practice may provide additional prognostic information for older adults with cancer above and beyond what is captured in routine clinical assessment including frailty.
{"title":"CT‐Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies","authors":"Smith Giri, Christian Harmon, Daniel Hess, Elizabeth M. Cespedes Feliciano, Ijeamaka Anyene Fumagalli, Bette Caan, Leon Lenchik, Karteek Popuri, Vincent Chow, Mirza Faisal Beg, Smita Bhatia, Grant R. Williams","doi":"10.1002/jcsm.13664","DOIUrl":"https://doi.org/10.1002/jcsm.13664","url":null,"abstract":"BackgroundOlder adults with cancer are at an increased risk of treatment related toxicities and early death. Routinely collected clinico‐demographic characteristics inadequately explain this increased risk limiting accurate prognostication. Prior studies have suggested that altered body composition and frailty are independently associated with worse survival among older adults with cancer; however, their combined influence remains unclear.MethodsWe used data from a single‐institution prospective cohort study of older adults (≥ 60 years) who underwent geriatric assessment (GA) at the time of initial consultation with a medical oncologist from September 2017 to December 2020 and available baseline abdominal computed tomography within 60 days of GA. Using multi‐slice CT images from T12 to L5 level, we assessed volumetric measures of skeletal muscle (SMV), visceral adipose tissue (VATV), subcutaneous adipose tissue (SATV) and averaged skeletal muscle density (SMD), computing sex‐specific <jats:italic>z</jats:italic> for each measure. Frailty was measured using a 44‐item frailty index using the deficit accumulation approach. Primary outcome of interest was overall survival (OS) defined as time from GA to death or last follow up. We used multivariable Cox regression model to study the independent association between the above four body composition measurements and OS adjusted for baseline confounders and frailty.ResultsWe included 459 patients with a mean age of 69.7 ± 7.5 years, 60% males and 77% non‐Hispanic Whites. Most had colorectal (27%) or pancreatic cancer (20%) and 48% had stage IV disease. Over a median follow up of 39.4 months, 209 patients (46%) died. In multivariable Cox regression models adjusted for age, sex, race, cancer type, cancer stage and frailty, skeletal muscle volume (HR 0.74; 95% CI 0.58–0.96; <jats:italic>p</jats:italic> = 0.02, per 1 SD increment) was independently associated with OS. The addition of body composition variables to baseline clinico‐demographic variables and frailty led to a slightly improved model discrimination.ConclusionsSMV is independently associated with OS among older adults with newly diagnosed gastrointestinal cancers. Capturing body composition measurements in oncology practice may provide additional prognostic information for older adults with cancer above and beyond what is captured in routine clinical assessment including frailty.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"92 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>We have read with interest the article by Setoyama Y et al. [<span>1</span>] titled ‘Association of dynapenic obesity with cardiovascular disease: The Hisayama Study.’ While this study provides valuable insights into the relationship between dynapenic obesity and cardiovascular disease risk, we would like to highlight three points that warrant further discussion.</p> <p>First, the authors introduce the concept of ‘dynapenic obesity’ and discuss it alongside ‘sarcopenic obesity’ in the introduction, citing multiple references related to sarcopenic obesity. However, according to the 2022 guidelines from the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO), sarcopenic obesity is specifically defined as the coexistence of obesity and sarcopenia [<span>2</span>]. In Setoyama et al.'s study, dynapenic obesity only considers handgrip strength and body mass index, whereas handgrip strength is just one dimension of assessing sarcopenia and cannot fully represent a sarcopenia diagnosis [<span>3</span>]. Therefore, the authors should not equate dynapenic obesity with sarcopenic obesity. This conceptual confusion may lead to misinterpretation and misapplication of the study results.</p> <p>Second, this study not only spans a median follow-up of 24 years but also assesses baseline handgrip strength and body mass index. Over such an extended follow-up period, important variables such as participants' physical function, height, weight, dietary habits, and physical activity are likely to have changed significantly. These changes would inevitably affect the association between exposure and outcome, and we consider this crucial limitation should be emphasized more strongly, with a discussion of its potential impact on the study findings.</p> <p>Third, from a statistical perspective, the study uses Cox proportional hazards models to analyse the relationship between dynapenic obesity and cardiovascular disease risk. However, given the long-term nature of the follow-up, the proportional hazards assumption may not hold. The impact of dynapenic obesity on cardiovascular disease risk might change over time. Therefore, we suggest that the authors consider using time-dependent Cox models or other statistical methods suitable for long-term follow-up data to more accurately capture the time-varying relationship between exposure and outcome [<span>4</span>].</p> <p>Additionally, the study employs multiple comparisons but does not appear to have applied any correction for multiple testing. This could increase the risk of Type I errors, leading to false-positive results. We recommend that the authors consider using appropriate methods for multiple comparison correction, such as the Bonferroni correction or false discovery rate methods [<span>5</span>].</p> <p>In conclusion, while Setoyama et al.'s study provides important insights into the relationship between dynapenic obesity and cardiovascular dis
{"title":"Comment on ‘Association Between Dynapenic Obesity and Risk of Cardiovascular Disease: The Hisayama Study’ by Setoyama et al.","authors":"Chang Liu, Fan Zhang, Min Cao","doi":"10.1002/jcsm.13684","DOIUrl":"https://doi.org/10.1002/jcsm.13684","url":null,"abstract":"<p>We have read with interest the article by Setoyama Y et al. [<span>1</span>] titled ‘Association of dynapenic obesity with cardiovascular disease: The Hisayama Study.’ While this study provides valuable insights into the relationship between dynapenic obesity and cardiovascular disease risk, we would like to highlight three points that warrant further discussion.</p>\u0000<p>First, the authors introduce the concept of ‘dynapenic obesity’ and discuss it alongside ‘sarcopenic obesity’ in the introduction, citing multiple references related to sarcopenic obesity. However, according to the 2022 guidelines from the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO), sarcopenic obesity is specifically defined as the coexistence of obesity and sarcopenia [<span>2</span>]. In Setoyama et al.'s study, dynapenic obesity only considers handgrip strength and body mass index, whereas handgrip strength is just one dimension of assessing sarcopenia and cannot fully represent a sarcopenia diagnosis [<span>3</span>]. Therefore, the authors should not equate dynapenic obesity with sarcopenic obesity. This conceptual confusion may lead to misinterpretation and misapplication of the study results.</p>\u0000<p>Second, this study not only spans a median follow-up of 24 years but also assesses baseline handgrip strength and body mass index. Over such an extended follow-up period, important variables such as participants' physical function, height, weight, dietary habits, and physical activity are likely to have changed significantly. These changes would inevitably affect the association between exposure and outcome, and we consider this crucial limitation should be emphasized more strongly, with a discussion of its potential impact on the study findings.</p>\u0000<p>Third, from a statistical perspective, the study uses Cox proportional hazards models to analyse the relationship between dynapenic obesity and cardiovascular disease risk. However, given the long-term nature of the follow-up, the proportional hazards assumption may not hold. The impact of dynapenic obesity on cardiovascular disease risk might change over time. Therefore, we suggest that the authors consider using time-dependent Cox models or other statistical methods suitable for long-term follow-up data to more accurately capture the time-varying relationship between exposure and outcome [<span>4</span>].</p>\u0000<p>Additionally, the study employs multiple comparisons but does not appear to have applied any correction for multiple testing. This could increase the risk of Type I errors, leading to false-positive results. We recommend that the authors consider using appropriate methods for multiple comparison correction, such as the Bonferroni correction or false discovery rate methods [<span>5</span>].</p>\u0000<p>In conclusion, while Setoyama et al.'s study provides important insights into the relationship between dynapenic obesity and cardiovascular dis","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"4 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Davide Acquarone, Alessandro Bertero, Mara Brancaccio, Matteo Sorge
Despite significant progress in understanding the molecular aetiology of muscle atrophy, there is still a great need for new targets and drugs capable of counteracting muscle wasting. The role of an impaired proteostasis as the underlying causal mechanism of muscle atrophy is a well‐established concept. From the earliest work on muscle atrophy and the identification of the first atrogenes, the hyper‐activation of the proteolytic systems, such as autophagy and the ubiquitin proteasome system, has been recognized as the major driver of atrophy. However, the role of other key regulators of proteostasis, the chaperone proteins, has been largely overlooked. Chaperone proteins play a pivotal role in protein folding and in preventing the aggregation of misfolded proteins. Indeed, some chaperones, such as αB‐crystallin and Hsp25, are involved in compensatory responses aimed at counteracting protein aggregation during sarcopenia. Chaperones also regulate different intracellular signalling pathways crucial for atrogene expression and the control of protein catabolism, such as the AKT and NF‐kB pathways, which are regulated by Hsp70 and Hsp90. Furthermore, the downregulation of certain chaperones causes severe muscle wasting per se and experimental strategies aimed at preventing this downregulation have shown promising results in mitigating or reversing muscle atrophy. This highlights the therapeutic potential of targeting chaperones and confirms their crucial anti‐atrophic functions. In this review, we summarize the most relevant data showing the modulation and the causative role of chaperone proteins in different types of skeletal muscle atrophies.
{"title":"Chaperone Proteins: The Rising Players in Muscle Atrophy","authors":"Davide Acquarone, Alessandro Bertero, Mara Brancaccio, Matteo Sorge","doi":"10.1002/jcsm.13659","DOIUrl":"https://doi.org/10.1002/jcsm.13659","url":null,"abstract":"Despite significant progress in understanding the molecular aetiology of muscle atrophy, there is still a great need for new targets and drugs capable of counteracting muscle wasting. The role of an impaired proteostasis as the underlying causal mechanism of muscle atrophy is a well‐established concept. From the earliest work on muscle atrophy and the identification of the first atrogenes, the hyper‐activation of the proteolytic systems, such as autophagy and the ubiquitin proteasome system, has been recognized as the major driver of atrophy. However, the role of other key regulators of proteostasis, the chaperone proteins, has been largely overlooked. Chaperone proteins play a pivotal role in protein folding and in preventing the aggregation of misfolded proteins. Indeed, some chaperones, such as αB‐crystallin and Hsp25, are involved in compensatory responses aimed at counteracting protein aggregation during sarcopenia. Chaperones also regulate different intracellular signalling pathways crucial for atrogene expression and the control of protein catabolism, such as the AKT and NF‐kB pathways, which are regulated by Hsp70 and Hsp90. Furthermore, the downregulation of certain chaperones causes severe muscle wasting per se and experimental strategies aimed at preventing this downregulation have shown promising results in mitigating or reversing muscle atrophy. This highlights the therapeutic potential of targeting chaperones and confirms their crucial anti‐atrophic functions. In this review, we summarize the most relevant data showing the modulation and the causative role of chaperone proteins in different types of skeletal muscle atrophies.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"22 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luke Aldrich, Theocharis Ispoglou, Konstantinos Prokopidis, Jasem Alqallaf, Oliver Wilson, Antonis Stavropoulos‐Kalinoglou
BackgroundAcute sarcopenia is sarcopenia lasting less than 6 months, typically following acute illness or injury. It may impact patient recovery and quality of life, advancing to chronic sarcopenia. However, its development and assessment remain poorly understood, particularly during hospitalisation. This systematic review aimed to elucidate the incidence of acute sarcopenia and examine changes in muscle parameters during hospitalisation.MethodsEighty‐eight papers were included in the narrative synthesis; 33 provided data for meta‐analyses on the effects of hospitalisation on handgrip strength (HGS), rectus femoris cross‐sectional area (RFCSA) and various muscle function tests. Meta‐regressions were performed for length of hospital stay (LoS) and age for all meta‐analyses; sex was also considered for HGS.ResultsAcute sarcopenia development was assessed in four studies with a pooled incidence of 18% during hospitalisation. Incidence was highest among trauma patients in intensive care (59%), whereas it was lower among medical and surgical patients (15%–20%). Time of development ranged from 4 to 44 days. HGS remained stable during hospitalisation (SMD = 0.05, 95% CI = −0.18:0.28, p = 0.67) as did knee extensor strength. LoS affected HGS performance (θ = 0.04, 95% CI = 0.001:0.09, p = 0.045) but age (p = 0.903) and sex (p = 0.434) did not. RFCSA, reduced by 16.5% over 3–21 days (SMD = −0.67, 95% CI = −0.92:−0.43, p < 0.001); LoS or time between scans did significantly predict the reduction (θ = −0.04, 95% CI = −0.077:−0.011, p = 0.012). Indices of muscle quality also reduced. Muscle function improved when assessed by the short physical performance battery (SMD = 0.86, 95% CI = 0.03:1.69, p = 0.046); there was no change in 6‐min walk (p = 0.22), timed up‐and‐go (p = 0.46) or gait speed tests (p = 0.98). The only significant predictor of timed up‐and‐go performance was age (θ = −0.11, 95% CI = −0.018:−0.005, p = 0.009).ConclusionsAssessment and understanding of acute sarcopenia in clinical settings are limited. Incidence varies between clinical conditions, and muscle parameters are affected differently. HGS and muscle function tests may not be sensitive enough to identify acute changes during hospitalisation. Currently, muscle health deterioration may be underdiagnosed impacting recovery, quality of life and overall health following hospitalisation. Further evaluation is necessary to determine the suitability of existing diagnostic criteria of acute sarcopenia. Muscle mass and quality indices might need to become the primary determinants for muscle health assessment in hospitalised populations.
{"title":"Acute Sarcopenia: Systematic Review and Meta‐Analysis on Its Incidence and Muscle Parameter Shifts During Hospitalisation","authors":"Luke Aldrich, Theocharis Ispoglou, Konstantinos Prokopidis, Jasem Alqallaf, Oliver Wilson, Antonis Stavropoulos‐Kalinoglou","doi":"10.1002/jcsm.13662","DOIUrl":"https://doi.org/10.1002/jcsm.13662","url":null,"abstract":"BackgroundAcute sarcopenia is sarcopenia lasting less than 6 months, typically following acute illness or injury. It may impact patient recovery and quality of life, advancing to chronic sarcopenia. However, its development and assessment remain poorly understood, particularly during hospitalisation. This systematic review aimed to elucidate the incidence of acute sarcopenia and examine changes in muscle parameters during hospitalisation.MethodsEighty‐eight papers were included in the narrative synthesis; 33 provided data for meta‐analyses on the effects of hospitalisation on handgrip strength (HGS), rectus femoris cross‐sectional area (RFCSA) and various muscle function tests. Meta‐regressions were performed for length of hospital stay (LoS) and age for all meta‐analyses; sex was also considered for HGS.ResultsAcute sarcopenia development was assessed in four studies with a pooled incidence of 18% during hospitalisation. Incidence was highest among trauma patients in intensive care (59%), whereas it was lower among medical and surgical patients (15%–20%). Time of development ranged from 4 to 44 days. HGS remained stable during hospitalisation (SMD = 0.05, 95% CI = −0.18:0.28, <jats:italic>p</jats:italic> = 0.67) as did knee extensor strength. LoS affected HGS performance (θ = 0.04, 95% CI = 0.001:0.09, <jats:italic>p</jats:italic> = 0.045) but age (<jats:italic>p</jats:italic> = 0.903) and sex (<jats:italic>p</jats:italic> = 0.434) did not. RFCSA, reduced by 16.5% over 3–21 days (SMD = −0.67, 95% CI = −0.92:−0.43, <jats:italic>p</jats:italic> < 0.001); LoS or time between scans did significantly predict the reduction (θ = −0.04, 95% CI = −0.077:−0.011, <jats:italic>p</jats:italic> = 0.012). Indices of muscle quality also reduced. Muscle function improved when assessed by the short physical performance battery (SMD = 0.86, 95% CI = 0.03:1.69, <jats:italic>p</jats:italic> = 0.046); there was no change in 6‐min walk (<jats:italic>p</jats:italic> = 0.22), timed up‐and‐go (<jats:italic>p</jats:italic> = 0.46) or gait speed tests (<jats:italic>p</jats:italic> = 0.98). The only significant predictor of timed up‐and‐go performance was age (θ = −0.11, 95% CI = −0.018:−0.005, <jats:italic>p</jats:italic> = 0.009).ConclusionsAssessment and understanding of acute sarcopenia in clinical settings are limited. Incidence varies between clinical conditions, and muscle parameters are affected differently. HGS and muscle function tests may not be sensitive enough to identify acute changes during hospitalisation. Currently, muscle health deterioration may be underdiagnosed impacting recovery, quality of life and overall health following hospitalisation. Further evaluation is necessary to determine the suitability of existing diagnostic criteria of acute sarcopenia. Muscle mass and quality indices might need to become the primary determinants for muscle health assessment in hospitalised populations.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"78 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：